Master of Science in Biomedical Sciences / Department of Anatomy and Physiology / Yongming Sang / Animal metabolic and immune systems integrate and inter-regulate to exert effective immune responses to distinct pathogens. The signaling pathway mediated by mechanistic target of rapamycin (mTOR) is critical in cellular metabolism and implicated in host antiviral responses. Recent studies highlight the significance of the mTOR signaling pathway in the interferon (IFN) response. Type I IFNs mediate host defense, particularly, against viral infections, and have myriad roles in antiviral innate and adaptive immunity. In addition to their well-known antiviral properties, type I IFNs also affect host metabolism. However, little is known about how animal type I IFN signaling coordinates immunometabolic reactions during antiviral defense. Therefore, understanding the interaction of mTOR signaling and the type I IFN system becomes increasingly important in potentiating antiviral immunity. Tissue macrophages (MФs) are a primary IFN producer during viral infection, and their polarization to different activation statuses is critical for regulation of immune and metabolic homeostasis. Using porcine reproductive and respiratory syndrome virus (PRRSV) as a model, we found that genes in the mTOR signaling pathway were regulated differently in PRRSV-infected porcine alveolar MФs at different activation statuses. Therefore we hypothesize that: 1) the mTOR signaling pathway involves host anti-PRRSV regulation; 2) mTOR signaling interacts with IFN signaling to modulate the antiviral response; and 3) different type I IFN subtypes (such as IFN-α1 and IFN-β) regulate mTOR signaling differently. We show that modulation of mTOR signaling regulated PRRSV infection in MARC-145 cells and porcine primary cells, in part, through regulating production and signaling of type I IFNs. In addition, expression and phosphorylation of two key components in the mTOR signaling pathway, AKT and p70 S6 kinase, were regulated by type I IFNs and PRRSV infection. Taken together, we determined that the mTOR signaling pathway, a key pathway in regulation of cell metabolism, also mediates the type I IFN response, a key immune response in PRRSV infection. Our findings reveal that the mTOR signaling pathway potentially has a bi-directional loop with the type I IFN system and implies that some components in the mTOR signaling pathway can serve as targets for augmentation of antiviral immunity and therapeutic designs.

Lithium is given to millions of bipolar disorder or post-traumatic disorder patients. The recent studies also support a role for lithium in treating neurodegenerative disease such as Parkinson's disease and stroke. Lithium treatment leads to lithium nephropathy, which includes lithium-induced nephrogenic diabetic insipidus (NDI), lithium-induced renal cell proliferation leading to the formation of microcysts in the kidney, and lithium-induced renal fibrosis. However, there is still a gap in understanding the mechanisms and signaling pathways involved in regulating lithium-induced nephropathy. mTOR pathway activation and primary cilia are known to be associated with the abnormal renal cell proliferation and the formation of renal cysts in polycystic kidney disease, a renal disease model similar to our lithium model. The activation of hedgehog pathway is associated with the renal fibrosis observed in the unilateral ureteral obstruction and unilateral ischemia reperfusion injury models of chronic renal injury. Thus, I hypothesize that mTOR signaling pathway, primary cilia and hedgehog pathway may all contribute to lithium-induced nephropathy. To address the hypothesis that the mTOR signaling pathway may be responsible for lithium-induced renal collecting duct proliferation, mTOR pathway activation was assessed in lithium-treated mice and lithium-treated mouse inner medullary collecting duct (mIMCD3) cells. Lithium activated mTOR signaling pathway in renal collecting duct cells both in vivo and in vitro. Rapamycin, an inhibitor of mTOR, blocked lithium-induced renal cell proliferation in renal cortex and medulla in vivo and in renal collecting duct cells in vitro, supporting the hypothesis. However, rapamycin did not improve lithium-induced reduction of urine osmolality, suggesting mTOR signaling pathway may not contribute to lithium-induced NDI. To address the hypothesis that primary cilia may be necessary for lithium-induced mTOR activation and renal cell proliferation, primary cilia deficient cells were used to assess mTOR pathway activation and cell proliferation in response to lithium treatment. The absence of primary cilia abolished lithium-induced activation of mTOR pathway and cell proliferation, which supports the hypothesis. To address the hypothesis that lithium elongates primary cilia length, which is mediated by mTOR signaling pathway, primary cilia length alternation was assessed in the kidney and in mIMCD3 cells in response to lithium treatment. Lithium increased primary cilia length in renal collecting duct cells of cortex, outer medulla, and inner medulla kidney regions in vivo and in mIMCD3 cells in vitro. Rapamycin reversed lithium-induced elongation of primary cilia in renal cortical and outer medullary collecting duct cells in vivo, and blocked the increase of primary cilia length in mIMCD3 cells in vitro, which support the hypothesis. To address the hypothesis that lithium activates the hedgehog pathway in a Smoothened (smo, a key regulator of the hedgehog pathway)-dependent manner in renal collecting duct cells, mIMCD3 cells were treated with lithium or lithium/Smo inhibitor or lithium/Smo activator. Hedgehog signaling pathway is activated by lithium in mIMCD3 cells, which is partially Smo-dependent. However, the role of hedgehog signaling pathway in regulating lithium-induced fibrosis was not assessed in the study. Future studies are required to determine the role of the hedgehog pathway in the lithium model.

No description available.

O carcinoma mucoepidermóide (CME) é o tumor mais comum entre as neoplasias malignas de glândula salivar. Recentemente, uma rara população de células com características de multipotência, autorrenovação e potencial tumorigênico, denominadas como células tronco tumorais (CTT), foi descrita no CME. As CTT são resistentes as terapias atuais, e têm sido consideradas responsáveis pela recorrência e metástase, levando a um pior prognóstico para o paciente. A descoberta de que as CTT do CME superexpressam componentes da via de sinalização mTOR, levantou a hipótese que os pacientes poderiam ser beneficiados com o uso inibidores de mTOR como terapia para eliminação das CTT. O objetivo desse estudo foi avaliar o potencial uso de inibidores de mTOR como terapia para o CME com foco em CTT, assim como, investigar o funcionamento da via de sinalização mTOR e os efeitos moleculares do tratamento com inibidores dessa via nas CTT do CME. Foi realizada imuno-histoquímica para p-mTOR e p-S6K-1 em casos de pacientes diagnosticados com CME, os resultados foram correlacionados com os dados clínicos dos pacientes e também foi realizada dupla marcação por imunofluorescência para ALDH/p-mTOR. Estudos in vitro foram realizados em 3 linhagens de CME (UM-HMC-1, -3A, -3B) e com inibidores da via de sinalização mTOR. Após exposição aos inibidores, realizou-se ensaios de western blot (proteínas da via mTOR e BMI-1), citometria de fluxo para ALDH/CD44; salisfera; e apoptose, esse último comparando com quimioterápicos utilizados atualmente. Adicionalmente, foi utilizado o silenciamento genético de mTOR para confirmar os resultados obtidos com inibidores químicos. Por fim, foram realizados ensaios in vivo com as células silenciadas e com o inibidor de mTOR tensirolimo. Os resultados evidenciaram que a via de sinalização mTOR está ativa no CME, é correlacionada com pior prognóstico clínico e está superexpressa nas CTT. O tratamento com inibidores da via mTOR levaram a diminuição da fração de CTT, devido a perda de autorrenovação e apoptose das CTT. A apoptose, junto a diminuição de p-AKT revelada por western blot, sugeriram que esteja ocorrendo inibição de mTORC2 nas CTT, um importante componente na eficácia do tratamento com inibição de mTOR no câncer. Além disso, também houve redução de vasos sanguíneos, nichos das CTT, e diminuição do crescimento tumoral com uso de inibidores ou silenciando mTOR in vivo. Coletivamente, os resultados mostraram que a inibição de mTOR foi capaz de agir nas CTT por mecanismos diretos (indução de apoptose e diminuição da autorrenovação) e indiretamente através da redução de angiogênese, sugerindo que o uso de inibidores de mTOR no tratamento do CME é uma estratégia molecular eficiente para a redução de CTT, e uma potencial terapia adjuvante. / Mucoepidermoid carcinoma (MEC) is the most common tumor among malignant salivary gland neoplasms. Recently, a rare population of multipotent, self-renewing, and tumorigenic cells, termed cancer stem cells (CSC), was described in MEC. CSC are resistant to current therapies, and have been considered responsible for recurrence and metastasis, leading to worse patient prognosis. The discovery that CSC from MEC overexpressed the mTOR signaling pathway raised the hypothesis that use of mTOR inhibitors as therapy for CSC elimination could benefit patients. The objective of this study was to evaluate the potential use of mTOR inhibitors as a therapy for MEC targeting CTT, as well to investigate the functioning of mTOR signaling pathway and the molecular effects of treatment with mTOR inhibitors in MEC CSC. Immunohistochemistry was performed for p-mTOR and p-S6K-1 in paraffin samples from patients diagnosed with MEC and results were correlated with clinical data, in addition, co-immunoflorescence was performed for ALDH/p-mTOR. In vitro studies were performed with 3 MEC cell lines (UM-HMC-1, -3A, -3B) and with inhibitors of the mTOR signaling pathway. After exposure to inhibitors the following assays were performed: western blot (mTOR signaling pathway proteins and BMI-1), flow cytometry for ALDH/CD44, salispheres, and apoptosis, the latter comparing with currently chemotherapeutic agents used as treatment for cancer patients. In addition, mTOR genetically silent was used to confirm results with chemical inhibitors. Finally, in vivo assays were performed with knockdown cells and with mTOR inhibitor temsirolimus treatment. Results showed that mTOR signaling pathway is active in MEC, it is correlated with worse clinical prognosis and it is overexpressed in CSC. Treatment with inhibitors of mTOR signaling pathway led to a decrease in CSC fraction, caused by loss of self-renewal and apoptosis. Apoptosis, together with the decrease in p-AKT revealed by western blot, suggest that inhibition of mTORC2, an important compound in the efficacy of mTOR inhibition for cancer treatment, is occurring. In addition, there was reduction of blood vessels, CSC niches, and decreased tumor growth using mTOR inhibitors or silencing mTOR. Collectively, results showed that inhibition of mTOR was able to act in CSC by direct mechanisms (induction of apoptosis, decreased self-renewal) and indirectly through reduction of angiogenesis, suggesting that the use of mTOR inhibitors in treatment of MEC is an efficient molecular strategy to reduce fraction of CSC, and a potential therapy.

O carcinoma de cabeça e pescoço é uma neoplasia maligna de origem epitelial que resulta em aproximadamente 500.000 novos casos por ano ao redor do mundo. Diversos estudos têm sido conduzidos de maneira a elucidar os mecanismos de proliferação e invasão desta doença, sendo a via de sinalização Akt/mTOR e proteínas relacionadas, apontada como uma das principais vias envolvidas em sua progressão. Sabe-se que células neoplásicas, bem como células de diferentes tecidos, podem ter seu comportamento modificado após terem sido irradiadas com laser em baixa intensidade (LLLT). Porém, os mecanismos de atuação da luz laser de baixa potência sobre estas células permanecem ainda não completamente esclarecidos. Portanto, o objetivo deste estudo foi o de analisar a viabilidade celular e expressão das proteínas Akt, pAkt, Hsp90, S6, pS6 e Ciclina D1 em duas linhagens celulares de carcinoma de boca (SCC9 e SCC25), bem como em uma linhagem de queratinócitos orais humanos com displasia (DOK) após irradiação com laser em baixa intensidade. O laser utilizado foi um diodo semicondutor de arseneto de Gálio e Alumínio (GaAlAs) operando nos comprimentos de onda vermelho (660nm) e infravermelho (780nm), com potência fixa em 40mW e três densidades de energia para cada comprimento de onda disponível: 2.05J/cm², 3.07J/cm² e 6.15J/cm². A análise de apoptose foi realizada por meio do teste de TUNEL e a expressão proteica foi obtida com imunofluorescência e western blotting. Após análise estatística por meio do método ANOVA dois critérios e testes de Tukey ou teste T de estudante, todos com nível de significância de 5%, pôde-se concluir que a LLLT induziu comportamentos distintos em cada uma das linhagens celulares utilizadas. Foi notado aumento, bem como diminuição da viabilidade celular, dependendo do comprimento de onda utilizado e das células irradiadas. A densidade de energia de 2.05J/cm² foi a que produziu efeitos mais significativos em SCC9. Para a linhagem celular SCC25, a dose mais relevante foi a de 3.07J/cm², enquanto que para a linhagem DOK, a dose de 6.15J/cm² causou efeitos mais proeminentes. Estas respectivas doses foram escolhidas para cada uma das linhagens para dar continuidade aos experimentos de Western Blotting e Imunofluorescência. Dentre os resultados mais relevantes obtidos com estas técnicas, pode-se citar a variação dos níveis de pS6 e Ciclina D1 para a linhagem DOK em determinados períodos. Já a linhagem SCC9 apresentou variação dos níveis de pAkt e Ciclina D1 nos períodos estudados. A linhagem SCC25 também teve as expressões de pAkt, pS6 e Ciclina D1 modificadas por LLLT. De maneira interessante, o aparecimento ou manutenção de uma isoforma de Hsp90 foi encontrado em SCC9 e SCC25 após irradiação laser. Por fim, a indução de apoptose foi detectada na linhagem SCC25. Em conclusão, pode-se dizer que a LLLT, como empregada neste estudo, foi capaz de aumentar a expressão de proteínas relacionadas à progressão e invasão em todas as linhagens estudadas. Além disso, a irradiação laser foi única, apesar de ter causado efeitos prolongados, algumas vezes até o último período estudado. / Head and neck squamous cell carcinoma (HNSCC) is an epithelial malignant neoplasm that accounts for approximately 500.000 new cases yearly around the world. Several studies have been conducted to elucidate the mechanisms of proliferation and invasion of this lesion, whereas the Akt/mTOR signaling pathway with its related proteins is being pointed out as one of the main pathways involved in HNSCC`s progression. Neoplastic cells, as well as cells that originate from different tissues may have their behavior modified by low level laser therapy (LLLT); however, the mechanisms through which the low level laser light interacts with these cells remain poorly understood. Thus, this study sought to evaluate the cell viability and the expression levels of Akt, pAkt, Hsp90, S6, pS6 and Cyclin D1 proteins in two oral squamous cell carcinoma cell lineages (SCC9 and SCC25) and in one oral dysplastic human keratinocyte cell line (DOK) after they had been treated with LLLT. The laser device was a semiconductor diode of Gallium and Aluminum Arsenate (GaAlAs), operating with wavelengths of 660nm (red) and 780nm (infrared), with a fixed power of 40mW and giving three different energy densities: 2.05J/cm², 3.07J/cm² and 6.15J/cm². Apoptosis was analyzed through TUNEL test and the protein expression was accessed with Immunofluorescence and Western blotting. After statistical analysis through two-way ANOVA and Tukey or Student`s T test, all of them with a level of significance of 5%, it was concluded that LLLT induced distinct behaviors to each of the studied cell lines. Increases and inhibitions in cell viabilities were detected depending on the wavelength and also on the irradiated cell line. The energy density of 2.05J/cm² produced the most significant findings over SCC9. On the other hand, in SCC25 the most relevant results were detected with 3.07J/cm², while the most prominent findings were seen with 6.15J/cm² when the cell line DOK was evaluated. In that way, these respective doses were chosen for each cell line to continue with Western blotting and Immunofluorescence. Among the most relevant findings, the variation of pS6 and Cyclin D1 levels can be cited for DOK in some evaluated periods. SCC9 presented both pAkt and Cyclin D1 variations in the studied periods. Besides that, SCC25 also had pAkt, pS6 and Cyclin D1 levels modified by LLLT. Interestingly, the appearance and maintenance of an Hsp90 isoform was found in SCC9 and SCC25 after laser irradiation. Moreover, the induction of apoptosis was detected for the SCC25 cell line. Finally, the LLLT employed herein was able to enhance the expression of proteins related to progression and invasion in all of the studied cell lines. In addition, there was a single laser irradiation, although it caused prolonged effects, sometimes through the latest evaluated period.

Le muscle squelettique s'adapte en réponse à diverses influences en modulant sa masse et ses propriétés contractiles et métaboliques. Il est ainsi rapporté que l'hypoxie sévère a un effet délétère sur la masse et les capacités oxydatives du muscle, et pourrait ralentir la maturation du phénotype contractile au cours du développement post-natal. Cependant, les mécanismes de contrôle de cette plasticité musculaire ne sont pas clairement identifiés. Le but de ce travail était de déterminer le rôle de l'hypoxie environnementale sur le contrôle de la masse et l'adaptation du phénotype du muscle en croissance (hypertrophie de surcharge du plantaris après ablation de ses muscles agonistes et régénération du soléaire après lésions étendues induites par la notexine). L'exposition hypoxique limite transitoirement l'hypertrophie induite par la surcharge fonctionnelle, tandis qu'elle accentue la fonte musculaire en réprimant la formation et la croissance des néo-fibres au cours des étapes précoces de la régénération. Ces résultats seraient en partie expliqués par la désactivation partielle de la principale voie de protéosynthèse, la voie mTOR, par un mécanisme indépendant d'Akt. Parmi les inhibiteurs endogènes de mTOR étudiés (REDD1, BNIP-3 et l'AMPK), nous montrons que l'activation prononcée de l'AMPK en hypoxie pourrait réprimer l'activité de mTOR au cours de la régénération, alors que le mécanisme responsable de l'inhibition de mTOR n'a pas pu être identifié dans le modèle de surcharge. Le système protéolytique ubiquitine/protéasome-dépendant, évalué à partir de l'expression des atrogènes MURF1 et MAFbx, pourrait également expliquer en partie l'altération de l'hypertrophie de surcharge en hypoxie. Nos résultats soulignent par ailleurs que l'activité des cellules satellites serait réprimée au cours des premiers jours de régénération musculaire, conduisant à réduire la formation et la croissance des myotubes. Malgré cette perturbation précoce de la croissance musculaire, l'exposition prolongée en hypoxie ne limite pas l'hypertrophie de surcharge et la récupération de la masse du muscle lésé. Ceci démontre que les signaux anaboliques induits dans ces deux situations de croissance musculaire l'emportent très largement sur les signaux cataboliques de l'hypoxie. L'analyse des propriétés métaboliques et contractiles met en évidence que l'hypoxie altère les capacités oxydatives du muscle en croissance, mais les mécanismes impliqués dans cette réponse adaptative restent à identifier. Par ailleurs, l'hypoxie ne constitue pas un stimulus métabolique suffisant pour altérer la transition du phénotype contractile du muscle en surcharge et la récupération complète du phénotype contractile du muscle lésé. Elle contribue uniquement à ralentir très modérément et transitoirement l'adaptation phénotypique du muscle en surcharge, et à modifier le profil contractile du muscle durant la phase de dégénérescence musculaire. / Skeletal muscle adapts to various influences, by modulating both its mass and contractile and metabolic properties. It was reported that severe hypoxia impairs muscle mass and oxidative capacities and could reduce the fast-to-slow fiber transition during post-natal development. However, mechanisms involved in muscle plasticity during hypoxia exposure are not clearly identified. This work aimed to determine the role played by ambient hypoxia on the control of muscle mass and muscle phenotype during muscle growth (functional overload-induced hypertrophy of plantaris after removal of its synergist muscles and regeneration of soleus after extensive injury induced by notexin injection). Hypoxia exposure transiently minimizes the overload-induced hypertrophy, while it enhances the muscle-mass loss by repressing the formation and growth of nascent fibers during the early steps of regeneration. These results could be partly due to an impairment of the mTOR signaling activation, the main pathway involved in protein synthesis, independently of Akt. Among the endogenous repressors of mTOR studied (REDD1, BNIP-3 and AMPK), we show that the marked activation of AMPK in hypoxia could repress mTOR activity during regeneration, whereas the mechanism involved in mTOR inhibition remains unknown in the overload model. The ubiquitin/proteasome-dependant system, assessed from expression of the two atrogenes MURF1 and MAFbx, could also partly explain the hypoxia-induced alteration of muscle hypertrophy. Nevertheless, our findings show that activity of satellite cells could be repressed during the first days of regeneration, leading to reduce formation and growth of myotubes. Although muscle growth is early impaired, prolonged hypoxia exposure does not limit the overload-induced hypertrophy and the muscle mass recovery of injured muscle. This demonstrates that anabolic signals induced in these models of drastic muscle growth widely prevail on hypoxia-induced catabolic signals. The analysis of metabolic and contractile properties shows that hypoxia alters oxidative capacities in growing muscle, but mechanisms involved in this adaptive response remain to be elucidated. Moreover, hypoxia is not a sufficient metabolic stimulus to impair the fast-to-slow fiber transition in overloaded muscle, and the complete recovery of the contractile phenotype in injured muscle. It only contributes to transiently and modestly slow down the fast-to-slow fiber shift in overloaded muscle, and to modify the contractile profile of muscle during the degeneration phase.

O carcinoma de cabeça e pescoço é uma neoplasia maligna de origem epitelial que resulta em aproximadamente 500.000 novos casos por ano ao redor do mundo. Diversos estudos têm sido conduzidos de maneira a elucidar os mecanismos de proliferação e invasão desta doença, sendo a via de sinalização Akt/mTOR e proteínas relacionadas, apontada como uma das principais vias envolvidas em sua progressão. Sabe-se que células neoplásicas, bem como células de diferentes tecidos, podem ter seu comportamento modificado após terem sido irradiadas com laser em baixa intensidade (LLLT). Porém, os mecanismos de atuação da luz laser de baixa potência sobre estas células permanecem ainda não completamente esclarecidos. Portanto, o objetivo deste estudo foi o de analisar a viabilidade celular e expressão das proteínas Akt, pAkt, Hsp90, S6, pS6 e Ciclina D1 em duas linhagens celulares de carcinoma de boca (SCC9 e SCC25), bem como em uma linhagem de queratinócitos orais humanos com displasia (DOK) após irradiação com laser em baixa intensidade. O laser utilizado foi um diodo semicondutor de arseneto de Gálio e Alumínio (GaAlAs) operando nos comprimentos de onda vermelho (660nm) e infravermelho (780nm), com potência fixa em 40mW e três densidades de energia para cada comprimento de onda disponível: 2.05J/cm², 3.07J/cm² e 6.15J/cm². A análise de apoptose foi realizada por meio do teste de TUNEL e a expressão proteica foi obtida com imunofluorescência e western blotting. Após análise estatística por meio do método ANOVA dois critérios e testes de Tukey ou teste T de estudante, todos com nível de significância de 5%, pôde-se concluir que a LLLT induziu comportamentos distintos em cada uma das linhagens celulares utilizadas. Foi notado aumento, bem como diminuição da viabilidade celular, dependendo do comprimento de onda utilizado e das células irradiadas. A densidade de energia de 2.05J/cm² foi a que produziu efeitos mais significativos em SCC9. Para a linhagem celular SCC25, a dose mais relevante foi a de 3.07J/cm², enquanto que para a linhagem DOK, a dose de 6.15J/cm² causou efeitos mais proeminentes. Estas respectivas doses foram escolhidas para cada uma das linhagens para dar continuidade aos experimentos de Western Blotting e Imunofluorescência. Dentre os resultados mais relevantes obtidos com estas técnicas, pode-se citar a variação dos níveis de pS6 e Ciclina D1 para a linhagem DOK em determinados períodos. Já a linhagem SCC9 apresentou variação dos níveis de pAkt e Ciclina D1 nos períodos estudados. A linhagem SCC25 também teve as expressões de pAkt, pS6 e Ciclina D1 modificadas por LLLT. De maneira interessante, o aparecimento ou manutenção de uma isoforma de Hsp90 foi encontrado em SCC9 e SCC25 após irradiação laser. Por fim, a indução de apoptose foi detectada na linhagem SCC25. Em conclusão, pode-se dizer que a LLLT, como empregada neste estudo, foi capaz de aumentar a expressão de proteínas relacionadas à progressão e invasão em todas as linhagens estudadas. Além disso, a irradiação laser foi única, apesar de ter causado efeitos prolongados, algumas vezes até o último período estudado. / Head and neck squamous cell carcinoma (HNSCC) is an epithelial malignant neoplasm that accounts for approximately 500.000 new cases yearly around the world. Several studies have been conducted to elucidate the mechanisms of proliferation and invasion of this lesion, whereas the Akt/mTOR signaling pathway with its related proteins is being pointed out as one of the main pathways involved in HNSCC`s progression. Neoplastic cells, as well as cells that originate from different tissues may have their behavior modified by low level laser therapy (LLLT); however, the mechanisms through which the low level laser light interacts with these cells remain poorly understood. Thus, this study sought to evaluate the cell viability and the expression levels of Akt, pAkt, Hsp90, S6, pS6 and Cyclin D1 proteins in two oral squamous cell carcinoma cell lineages (SCC9 and SCC25) and in one oral dysplastic human keratinocyte cell line (DOK) after they had been treated with LLLT. The laser device was a semiconductor diode of Gallium and Aluminum Arsenate (GaAlAs), operating with wavelengths of 660nm (red) and 780nm (infrared), with a fixed power of 40mW and giving three different energy densities: 2.05J/cm², 3.07J/cm² and 6.15J/cm². Apoptosis was analyzed through TUNEL test and the protein expression was accessed with Immunofluorescence and Western blotting. After statistical analysis through two-way ANOVA and Tukey or Student`s T test, all of them with a level of significance of 5%, it was concluded that LLLT induced distinct behaviors to each of the studied cell lines. Increases and inhibitions in cell viabilities were detected depending on the wavelength and also on the irradiated cell line. The energy density of 2.05J/cm² produced the most significant findings over SCC9. On the other hand, in SCC25 the most relevant results were detected with 3.07J/cm², while the most prominent findings were seen with 6.15J/cm² when the cell line DOK was evaluated. In that way, these respective doses were chosen for each cell line to continue with Western blotting and Immunofluorescence. Among the most relevant findings, the variation of pS6 and Cyclin D1 levels can be cited for DOK in some evaluated periods. SCC9 presented both pAkt and Cyclin D1 variations in the studied periods. Besides that, SCC25 also had pAkt, pS6 and Cyclin D1 levels modified by LLLT. Interestingly, the appearance and maintenance of an Hsp90 isoform was found in SCC9 and SCC25 after laser irradiation. Moreover, the induction of apoptosis was detected for the SCC25 cell line. Finally, the LLLT employed herein was able to enhance the expression of proteins related to progression and invasion in all of the studied cell lines. In addition, there was a single laser irradiation, although it caused prolonged effects, sometimes through the latest evaluated period.

Thèse numérisée par la Division de la gestion de documents et des archives de l'Université de Montréal.

O carcinoma epidermóide bucal (CEC) é uma neoplasia maligna com alta morbidade e mortalidade e de difícil tratamento. O tratamento convencional para o CEC inclui cirurgia e radioterapia, seguida ou não de quimioterapia. Apesar de serem amplamente difundidos, esses tratamentos podem ser ineficazes para alguns CECs resistentes. A terapia fotodinâmica (PDT) oncológica tem sido utilizada para o tratamento adjuvante do CEC bucal, principalmente nos casos menos invasivos e que necessitam de redução do tumor para a ressecção cirúrgica. Contudo, semelhantemente aos tratamentos convencionais, a PDT pode também induzir o aparecimento de populações celulares resistentes, fato já descrito para carcinoma cutâneo, adenocarcinoma de cólon e adenocarcinoma mamário. A hipótese de que células de CEC bucal possam desenvolver resistência à PDT ainda não foi testada. Portanto, o objetivo deste trabalho foi verificar se células de CEC bucal (SCC9) desenvolvem resistência a ciclos repetidos de PDT mediada pelo ácido 5- aminolevulínico (5-ALA-PDT) e avaliar se nesse processo ocorre modificação da expressão de marcadores relacionados a sobrevivência celular (NF?B, Bcl-2, iNOS, mTOR e Akt). Foi utilizada linhagem de células de CEC bucal (SCC9), submetida às seguintes condições: 1) Controle - células cultivadas sem nenhum tratamento; 2) ALA - células incubadas com 5-ALA (1mM durante 4 horas); 3) LED - tratadas com iluminação LED (630nm, 5,86J/cm2, 22,5J, 150mW, 150s); 4) PDT - tratadas com 5- ALA-PDT, com os protocolos do grupo ALA e LED combinados, gerando dose letal de 90%. Inicialmente foi realizado somente um ciclo de PDT, sendo avaliada a viabilidade celular em todos os grupos após 24, 48, 72 e 120h da irradiação. Também foi realizado ensaio de detecção da fragmentação de DNA (TUNEL) e análise por imunofluorescência da expressão das proteínas NF?B, Bcl-2, iNOS, pmTOR e pAkt nas células viáveis. Como resultado desse primeiro tratamento com 5-ALA-PDT, observou-se que as células sobreviventes ao tratamento apresentaram intensa marcação para pmTOR e exibiram potencial de crescimento durante o período analisado. Após esses ensaios, as células que sobreviveram a essa primeira sessão foram coletadas, replaqueadas e novamente cultivadas, sendo então submetidas a novo ciclo de 5-ALA-PDT. Esse processo foi realizado 5 vezes, variando-se a intensidade de irradiação à medida que se observava aumento na viabilidade celular. As populações celulares que exibiram viabilidade 1,5 vezes maior do que a detectada no primeiro ciclo PDT foram consideradas resistentes ao tratamento. Os mesmos marcadores analisados no primeiro ciclo de PDT foram novamente avaliados nas populações resistentes. Foram obtidas quatro populações celulares resistentes, com viabilidade de até 4,6 vezes maior do que a do primeiro ciclo de PDT e irradiação com LED que variou de 5,86 a 9,38J/cm2. A população mais resistente apresentou ainda menor intensidade de protoporfirina IX, maior capacidade de migração e modificação na morfologia nuclear. As populações resistentes testadas exibiram aumento na expressão de pNF?B, iNOS, pmTOR e pAkt, mas não da proteína anti-apoptótica Bcl- 2. Ensaio in vivo foi também conduzido em ratos, nos quais CEC bucal foi quimicamente induzido e tratado ou não com 5-ALA-PDT. Houve intensa expressão imuno-histoquímica das proteínas pNF?B, Bcl-2, iNOS, pmTOR e pAkt em relação ao controle não tratado, nas células adjacentes à área de necrose provocada pela PDT. Concluiu-se que as células de CEC bucal tratadas com 5-ALA-PDT a uma dose de 90% de letalidade desenvolveram viabilidade crescente após ciclos repetidos do tratamento, bem como exibiram superexpressão de proteínas relacionadas à sobrevivência celular, tanto in vitro quanto in vivo. Esses fatos, aliados à maior capacidade de migração, sugerem a aquisição de fenótipo de resistência à 5-ALAPDT. Esse aspecto deve ser cuidadosamente considerado no momento da instituição dessa terapia para os CECs bucais. / Oral squamous cell carcinoma (SCC) is a malignant tumor with high morbidity and mortality rates, and it is difficult to treat. Conventional treatment for oral SCCs includes surgery and radiotherapy that may be followed by chemotherapy. Although these treatments are widely used, they are ineffective against some resistant tumors. Oncologic photodynamic therapy (PDT) has been used as an adjuvant treatment for oral SCCs, especially in less invasive cases that require tumor reduction before surgical resection. However, like conventional treatments, PDT can induce the occurrence of resistant cell populations such as cutaneous carcinomas and colon and breast adenocarcinomas. The hypothesis that oral SCCs develop resistance to PDT has not yet been tested. Therefore, the aims of this study were to investigate whether oral SCCs (SCC9) develop resistance to several cycles of 5-aminolevulinic acidmediated PDT (5-ALA-PDT) and to determine whether the expression of markers associated with cell survival (NF?B, Bcl-2, iNOS, mTOR, and Akt) is altered during this process. An oral SCC (SCC9) cell line was used, which was subjected to the following conditions: 1) Control: cultured without any treatment; 2) ALA: incubated with 5-ALA (1 mM for 4 h); 3) LED: treated with LED light (630 nm, 5.86 J/cm2, 22.5 J, 150 mW, 150 s); and 4) PDT: treated with 5-ALA-PDT (with the protocols of the ALA and LED groups combined) generating a lethal dose of 90%. Initially, only one cycle of PDT was administered, and cell viability was determined in all groups 24, 48, 72, and 120 h after irradiation. Subsequently, the DNA fragmentation detection assay (TUNEL) and immunofluorescence analysis of the expression of proteins NF?B, Bcl-2, iNOS, pmTOR, and pAkt were performed on viable cells. The fraction of cells that survived the first treatment with 5-ALA-PDT exhibited intense staining for pmTOR and growth potential during the testing period. After these assays, the cells that survived the first cycle were collected, plated, and cultured and were subjected to another cycle of 5- ALA-PDT. This process was repeated five times at various irradiation intensities, and cell viability gradually increased. The cell populations that exhibited 1.5-times higher viability than that detected after the first PDT cycle were considered to be resistant to treatment. The markers analyzed after the first PDT cycle were again assessed in the resistant populations. Four resistant cell populations were obtained with a viability of up to 4.6-times higher than that of the first PDT cycle and LED light treatment, which varied between 5.86 and 9.38J/cm2. The most resistant population exhibited lower intensity of protoporphyrin IX, higher migration capacity, and changes in nuclear morphology. The resistant populations tested showed increased expression of pNF?B, iNOS, pmTOR, and pAkt, but not of the anti-apoptotic Bcl-2 protein. Moreover, an in vivo assay was conducted in rats; oral SCCs were chemically induced and treated with 5-ALA-PDT. The intensity of the immunohistochemical expression of proteins pNF?B, Bcl-2, iNOS, pmTOR, and pAkt in cells adjacent to the area with necrosis caused by PDT was higher than that observed in the untreated control. In conclusion, oral SCCs treated with 5-ALA-PDT at a lethal dose of 90% exhibited increasing viability after several treatment cycles and overexpression of proteins associated with cell survival both in vitro and in vivo. These results, together with the higher migration capacity, suggest the acquisition of the phenotype of resistance to 5-ALA-PDT. This aspect should be carefully considered when initiating this therapy for oral SCCs.

O carcinoma epidermóide bucal (CEC) é uma neoplasia maligna com alta morbidade e mortalidade e de difícil tratamento. O tratamento convencional para o CEC inclui cirurgia e radioterapia, seguida ou não de quimioterapia. Apesar de serem amplamente difundidos, esses tratamentos podem ser ineficazes para alguns CECs resistentes. A terapia fotodinâmica (PDT) oncológica tem sido utilizada para o tratamento adjuvante do CEC bucal, principalmente nos casos menos invasivos e que necessitam de redução do tumor para a ressecção cirúrgica. Contudo, semelhantemente aos tratamentos convencionais, a PDT pode também induzir o aparecimento de populações celulares resistentes, fato já descrito para carcinoma cutâneo, adenocarcinoma de cólon e adenocarcinoma mamário. A hipótese de que células de CEC bucal possam desenvolver resistência à PDT ainda não foi testada. Portanto, o objetivo deste trabalho foi verificar se células de CEC bucal (SCC9) desenvolvem resistência a ciclos repetidos de PDT mediada pelo ácido 5- aminolevulínico (5-ALA-PDT) e avaliar se nesse processo ocorre modificação da expressão de marcadores relacionados a sobrevivência celular (NF?B, Bcl-2, iNOS, mTOR e Akt). Foi utilizada linhagem de células de CEC bucal (SCC9), submetida às seguintes condições: 1) Controle - células cultivadas sem nenhum tratamento; 2) ALA - células incubadas com 5-ALA (1mM durante 4 horas); 3) LED - tratadas com iluminação LED (630nm, 5,86J/cm2, 22,5J, 150mW, 150s); 4) PDT - tratadas com 5- ALA-PDT, com os protocolos do grupo ALA e LED combinados, gerando dose letal de 90%. Inicialmente foi realizado somente um ciclo de PDT, sendo avaliada a viabilidade celular em todos os grupos após 24, 48, 72 e 120h da irradiação. Também foi realizado ensaio de detecção da fragmentação de DNA (TUNEL) e análise por imunofluorescência da expressão das proteínas NF?B, Bcl-2, iNOS, pmTOR e pAkt nas células viáveis. Como resultado desse primeiro tratamento com 5-ALA-PDT, observou-se que as células sobreviventes ao tratamento apresentaram intensa marcação para pmTOR e exibiram potencial de crescimento durante o período analisado. Após esses ensaios, as células que sobreviveram a essa primeira sessão foram coletadas, replaqueadas e novamente cultivadas, sendo então submetidas a novo ciclo de 5-ALA-PDT. Esse processo foi realizado 5 vezes, variando-se a intensidade de irradiação à medida que se observava aumento na viabilidade celular. As populações celulares que exibiram viabilidade 1,5 vezes maior do que a detectada no primeiro ciclo PDT foram consideradas resistentes ao tratamento. Os mesmos marcadores analisados no primeiro ciclo de PDT foram novamente avaliados nas populações resistentes. Foram obtidas quatro populações celulares resistentes, com viabilidade de até 4,6 vezes maior do que a do primeiro ciclo de PDT e irradiação com LED que variou de 5,86 a 9,38J/cm2. A população mais resistente apresentou ainda menor intensidade de protoporfirina IX, maior capacidade de migração e modificação na morfologia nuclear. As populações resistentes testadas exibiram aumento na expressão de pNF?B, iNOS, pmTOR e pAkt, mas não da proteína anti-apoptótica Bcl- 2. Ensaio in vivo foi também conduzido em ratos, nos quais CEC bucal foi quimicamente induzido e tratado ou não com 5-ALA-PDT. Houve intensa expressão imuno-histoquímica das proteínas pNF?B, Bcl-2, iNOS, pmTOR e pAkt em relação ao controle não tratado, nas células adjacentes à área de necrose provocada pela PDT. Concluiu-se que as células de CEC bucal tratadas com 5-ALA-PDT a uma dose de 90% de letalidade desenvolveram viabilidade crescente após ciclos repetidos do tratamento, bem como exibiram superexpressão de proteínas relacionadas à sobrevivência celular, tanto in vitro quanto in vivo. Esses fatos, aliados à maior capacidade de migração, sugerem a aquisição de fenótipo de resistência à 5-ALAPDT. Esse aspecto deve ser cuidadosamente considerado no momento da instituição dessa terapia para os CECs bucais. / Oral squamous cell carcinoma (SCC) is a malignant tumor with high morbidity and mortality rates, and it is difficult to treat. Conventional treatment for oral SCCs includes surgery and radiotherapy that may be followed by chemotherapy. Although these treatments are widely used, they are ineffective against some resistant tumors. Oncologic photodynamic therapy (PDT) has been used as an adjuvant treatment for oral SCCs, especially in less invasive cases that require tumor reduction before surgical resection. However, like conventional treatments, PDT can induce the occurrence of resistant cell populations such as cutaneous carcinomas and colon and breast adenocarcinomas. The hypothesis that oral SCCs develop resistance to PDT has not yet been tested. Therefore, the aims of this study were to investigate whether oral SCCs (SCC9) develop resistance to several cycles of 5-aminolevulinic acidmediated PDT (5-ALA-PDT) and to determine whether the expression of markers associated with cell survival (NF?B, Bcl-2, iNOS, mTOR, and Akt) is altered during this process. An oral SCC (SCC9) cell line was used, which was subjected to the following conditions: 1) Control: cultured without any treatment; 2) ALA: incubated with 5-ALA (1 mM for 4 h); 3) LED: treated with LED light (630 nm, 5.86 J/cm2, 22.5 J, 150 mW, 150 s); and 4) PDT: treated with 5-ALA-PDT (with the protocols of the ALA and LED groups combined) generating a lethal dose of 90%. Initially, only one cycle of PDT was administered, and cell viability was determined in all groups 24, 48, 72, and 120 h after irradiation. Subsequently, the DNA fragmentation detection assay (TUNEL) and immunofluorescence analysis of the expression of proteins NF?B, Bcl-2, iNOS, pmTOR, and pAkt were performed on viable cells. The fraction of cells that survived the first treatment with 5-ALA-PDT exhibited intense staining for pmTOR and growth potential during the testing period. After these assays, the cells that survived the first cycle were collected, plated, and cultured and were subjected to another cycle of 5- ALA-PDT. This process was repeated five times at various irradiation intensities, and cell viability gradually increased. The cell populations that exhibited 1.5-times higher viability than that detected after the first PDT cycle were considered to be resistant to treatment. The markers analyzed after the first PDT cycle were again assessed in the resistant populations. Four resistant cell populations were obtained with a viability of up to 4.6-times higher than that of the first PDT cycle and LED light treatment, which varied between 5.86 and 9.38J/cm2. The most resistant population exhibited lower intensity of protoporphyrin IX, higher migration capacity, and changes in nuclear morphology. The resistant populations tested showed increased expression of pNF?B, iNOS, pmTOR, and pAkt, but not of the anti-apoptotic Bcl-2 protein. Moreover, an in vivo assay was conducted in rats; oral SCCs were chemically induced and treated with 5-ALA-PDT. The intensity of the immunohistochemical expression of proteins pNF?B, Bcl-2, iNOS, pmTOR, and pAkt in cells adjacent to the area with necrosis caused by PDT was higher than that observed in the untreated control. In conclusion, oral SCCs treated with 5-ALA-PDT at a lethal dose of 90% exhibited increasing viability after several treatment cycles and overexpression of proteins associated with cell survival both in vitro and in vivo. These results, together with the higher migration capacity, suggest the acquisition of the phenotype of resistance to 5-ALA-PDT. This aspect should be carefully considered when initiating this therapy for oral SCCs.